Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioterrorism legislation

This article was originally published in The Gray Sheet

Executive Summary

Senate bill (1764) sponsored by Sen. Lieberman (D-Conn.) would give net operating loss refunds for biotech companies researching diagnostic devices for biological or chemical agents used in terrorist attacks. S 1764 is expected to merge with the Bioweapons Preparedness Act of 2001 (S 1715), sponsored by Sens. Frist (R-Tenn.) and Kennedy (D-Mass.), which grants the Office of Homeland Security the authority to set research priorities that would help fight bioterrorism. Companies working on named priorities would be eligible for incentives including a zero capital gains tax rate on any gains realized on the stock. The bill would apply to firms with less than $750,000 in paid-in capital...

You may also be interested in...



Lieberman Counter-Terrorism Bill Brings Diagnostic Incentives Into The Mix

Sen. Joe Lieberman's (D-Conn.) bill to provide incentives for development of bioterrorism countermeasures is being revised to increase attention on diagnostics

Industry, Agencies Are Making COVID-19 Partnerships Easy

Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.

COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions

The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.

UsernamePublicRestriction

Register

MT015802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel